KP Tissue Inc.
KP Tissue Inc. Fundamental Analysis
KP Tissue Inc. (KPTSF) shows weak financial fundamentals with a PE ratio of 27.96, profit margin of 0.00%, and ROE of 5.62%. The company generates N/A in annual revenue with weak year-over-year growth of 0.00%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 30.6/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze KPTSF's fundamental strength across five key dimensions:
Efficiency Score
WeakKPTSF struggles to generate sufficient returns from assets.
Valuation Score
ModerateKPTSF shows balanced valuation metrics.
Growth Score
WeakKPTSF faces weak or negative growth trends.
Financial Health Score
ModerateKPTSF shows balanced financial health with some risks.
Profitability Score
WeakKPTSF struggles to sustain strong margins.
Key Financial Metrics
Is KPTSF Expensive or Cheap?
P/E Ratio
KPTSF trades at 27.96 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, KPTSF's PEG of -0.43 indicates potential undervaluation.
Price to Book
The market values KP Tissue Inc. at 1.56 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 0.51 times EBITDA. This is generally considered low.
How Well Does KPTSF Make Money?
Net Profit Margin
For every $100 in sales, KP Tissue Inc. keeps $0.00 as profit after all expenses.
Operating Margin
Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $5.62 in profit for every $100 of shareholder equity.
ROA
KP Tissue Inc. generates $5.44 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
KPTSF converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
27.96
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.43
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.56
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.00
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.00
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.06
vs 25 benchmark
ROA
Return on assets percentage
0.05
vs 25 benchmark
ROCE
Return on capital employed
0.00
vs 25 benchmark
How KPTSF Stacks Against Its Sector Peers
| Metric | KPTSF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 27.96 | 22.56 | Worse (Expensive) |
| ROE | 5.62% | 1288.00% | Weak |
| Net Margin | 0.00% | -5952.00% (disorted) | Weak |
| Debt/Equity | 0.00 | 0.81 | Strong (Low Leverage) |
| Current Ratio | 1.00 | 2.41 | Neutral |
| ROA | 5.44% | -197304.00% (disorted) | Weak |
KPTSF outperforms its industry in 1 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews KP Tissue Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
0.00%
Industry Style: Defensive, Dividend, Low Volatility
DecliningEPS CAGR
135.65%
Industry Style: Defensive, Dividend, Low Volatility
High GrowthFCF CAGR
100.00%
Industry Style: Defensive, Dividend, Low Volatility
High Growth